Aptinyx (NASDAQ:APTX) has completed enrollment in its ongoing Phase 2 exploratory study of NYX-783
to evaluate the safety and efficacy of NYX-783 in patients with
post-traumatic stress disorder (PTSD). The company anticipates data in
late 2020.
The primary efficacy endpoint is the change in
CAPS-5 (Clinician-Administered PTSD Scale for the DSM-5) total score and
sub-scores from baseline to the end of each of the four-week treatment
periods.
Additional endpoints evaluate the safety and
tolerability of NYX-783 on various PTSD symptoms, including sleep
quality, cognitive function, anxiety, and depression in PTSD patients.
The data are expected to inform future development plans for NYX-783 in PTSD.
https://seekingalpha.com/news/3584138-aptinyx-completes-enrollment-in-mid-stage-nyxminus-783-trial-in-ptsd
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.